Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Company Formed to Develop Spore-Based Next-Generation Vaccines

By BiotechDaily International staff writers
Posted on 06 Nov 2012
Scientists at Royal Holloway, University of London (London, UK), have developed a pioneering method of vaccination that served as the basis for receiving private seed investment used to form the new company, Holloway Immunology, to further develop the vaccine technology. The company is currently seeking additional investors to help fast track implementation of this new form of vaccine delivery.

Prof. Simon Cutting led the development using probiotic spores. He and his laboratory had been carrying out fundamental biology studies of Bacillus subtilis, which forms spores that can last millions of years before germinating under appropriate conditions. They later found that Bacillus spores can also act as effective vehicles to carry antigens and promote an immune response. "Rather than requiring needle delivery, vaccines based on Bacillus spores can be delivered via a nasal spray, or as an oral liquid or capsule. Alternatively, they can be administered via a small soluble film placed under the tongue [...]. As spores are exceptionally stable, vaccines based on Bacillus do not require cold-chain storage, alleviating a further issue with current vaccine approaches," explained Prof. Cutting. Besides eliminating pain associated with needles, oral vaccines are also safer to administer (especially in developing countries), inexpensive to produce, easier to store, and reduce concerns of adverse reactions.

Prof. Cutting and his team have carried out preclinical evaluation of Bacillus-based vaccines for a number of diseases including tuberculosis (TB), influenza, and tetanus. A Bacillus-based vaccine could boost the immunity provided by, or possibly even replace, existing vaccines against these diseases. They have also begun investigating the potential use of this technology against Clostridium difficile. “There is no vaccine against the disease, and although several approaches are currently undergoing clinical trials, none are expected to provide full protection," said Prof. Cutting. Also, unlike other current approaches, oral delivery can cause a more specific immune response in the gastrointestinal tract to more effectively eliminate C.difficile.

Holloway Immunology will initially concentrate development of the Bacillus spore based technology for three lead vaccines: against TB, influenza, and C. difficile.

Related Links:

Royal Holloway, University of London






BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
comments powered by Disqus

Channels

Genomics/Proteomics

view channel

MicroRNA Panel Identifies Mild Brain Trauma in a Mouse Model

A study conducted on a mouse model found that a panel of 13 serum microRNAs (miRNAs) could be used to identify the severity of damage to the brain and the risk of developing adverse effects following mild traumatic brain injury (mTBI). MTBI is a heterogeneous injury that may lead to the development of neurological and... Read more

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: Mouse kidneys, liver, and pancreas imaged after treatment with a variety of protocols: a saline solution, Scale, SeeDB (see deep brain), CUBIC, and carotid body (CB) perfusion (which was used in this study) (Photo courtesy of RIKEN Quantitative Biology Center).

Nearly Transparent Mice Offers Potential of Whole-Organism Imaging

Japanese researchers have developed a method that combines tissue decolorization and light-sheet fluorescent microscopy to take extremely detailed images of the interior of individual organs and even entire... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.